ResearcherStanford MedicineActive in the last 2 years

Aya Kamaya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5159-9506; OpenAlex author ID A5015205859. Sources: ClinicalTrials.gov.

Their work

Papers: 2
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Trials 1

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgi… Principal investigator NCT01326364 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sherif B. Elsherif · 1 shared paper, 2026 · strength 0.39
- Paper Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liqui… DOI 10.1007/s00261-026-05470-9 ↗
Justin R. Tse · 1 shared paper, 2026 · strength 0.39
- Paper Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liqui… DOI 10.1007/s00261-026-05470-9 ↗
George A. Poultsides · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Albert C. Koong · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
James M. Ford · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Brendan Christopher Visser · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Pamela L. Kunz · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Erqi Liu Pollom · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Muthuraman Alagappan · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Jeffrey Allen Norton · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
Daniel Tandel Chang · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗
George Albert Fisher · 1 shared paper, 2014 · strength 0.04
- Paper Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. DOI 10.1016/j.ijrobp.2014.06.066 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.